Skip to main content

Year: 2023

Speedemissions, Inc. Now Accepting Contributions from Pace University Students, Alumni and Faculty for its $100,000 “Project Planet Young Entrepreneur” Competition

Company to Award Cash & Services Grant to Contributor Chosen as Best Innovative Solution to Guard Our Planet from Climate Disaster ATLANTA, Oct. 24, 2023 (GLOBE NEWSWIRE) — Speedemissions, Inc. (OTC Markets Expert Market: SPMI) (the “Company”) a retail brand emissions testing and safety inspections company, operating nineteen stores in the Atlanta and St. Louis markets, is pleased to announce that that it is now accepting formal written contributions to its Project Planet Young Entrepreneur competition. Project Planet Young Entrepreneur is a collaboration between Speedemissions and the Pace University Lubin School of Business that will award a $100,000 grant, consisting of $15,000 cash plus in-kind professional services of mentoring, public relations, and network connections to the qualifying Pace University innovator who...

Continue reading

Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare

Lincare to distribute Vivos oral appliances through an exclusive nationwide agreement LITTLETON, Colo., Oct. 24, 2023 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS a leading medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, has signed a U.S. nationwide distribution agreement with Lincare, a leading supplier of in-home respiratory therapy products and services for approximately 1.8 million patients. The agreement follows the successful conclusion of a distribution pilot with Lincare, and marks an important milestone in Vivos’ strategy to engage with leading durable medical equipment (DME) companies in the United States. Vivos has agreed that Lincare will have a six-month exclusivity...

Continue reading

Else Nutrition Announces a Leading Canadian Grocery Store Chain First to List its Whole Plant-Based Ready-to-Drink Kids’ Nutritional Shakes

Retail Chain to Offer Else’s Unique Plant-Based RTD Kids’ Nutritional Shakes in Over 100 Stores, Bringing Great Taste and 40% Lower Sugar Content to Canadian Families in November 2023Canadian RTD LaunchCanadian RTD LaunchVANCOUVER, British Columbia, Oct. 24, 2023 (GLOBE NEWSWIRE) — ELSE NUTRITION HOLDINGS INC. (BABY) (BABYF) (0YL.F) (“Else” or the “Company”), announces that its innovative Ready-To-Drink (RTD) Kids’ Nutritional Shakes will be the first of its kind to hit the shelves of over 100 stores in November this year, in one of Canada’s leading grocery chain stores in Ontario. This listing, in addition to all other Else products already listed with the chain, marks a significant stride in Else’s Canadian market penetration strategy, providing a groundbreaking, tasteful,...

Continue reading

SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

Finance leader joins SAB with more than 25 years of experience as a leading biotech equity research analyst SIOUX FALLS, S.D., Oct. 24, 2023 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), today announced that Michael G. King Jr. has been named Chief Financial Officer. SAB is a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a fully-human anti-thymocyte immunoglobulin (hIgG) that may delay the onset or progression of type 1 diabetes (T1D). Mr. King has extensive experience and prior success as an award-winning biotechnology research analyst and senior advisor with more than 25 years of experience with investors, banking institutions and thought leaders in various pharmaceutical disciplines. Mr. King, who starts his new role on Oct. 30, replaces Russell Beyer, who is expected...

Continue reading

Brixton Metals Yields up to 33% Copper and 39 g/t Gold from 2023 Surface Sampling Results at the East Target and South Target, Thorn Project

Figure 1Location Map of the Thorn Project with Copper Geochemistry. https://brixtonmetals.com/wp-content/uploads/2023/10/image-18.pngFigure 2Location Map of the South Target with Gold Geochemistry. https://brixtonmetals.com/wp-content/uploads/2023/10/image-19.pngFigure 3Location Map of the Icy Zone, East Target with Gold & Copper Geochemistry. https://brixtonmetals.com/wp-content/uploads/2023/10/image-20.pngFigure 4Location Map of the Metla Target with Gold & Copper Geochemistry. https://brixtonmetals.com/wp-content/uploads/2023/10/image-21.pngFigure 5Location Map of the Plum Target with Gold & Copper Geochemistry. https://brixtonmetals.com/wp-content/uploads/2023/10/image-22.pngFigure 6Location Map of the South Trapper Target with Gold & Copper Geochemistry. https://brixtonmetals.com/wp-content/uploads/2023/10/image-23.pngFigure...

Continue reading

PyroGenesis Announces $360,000 Initial Contract for a Plasma-Based PACWAD System for Chemical Warfare Waste Destruction

Helping European Union Sappers Eliminate Legacy Weapons MONTREAL, Oct. 24, 2023 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (NASDAQ: PYR) (FRA: 8PY) a high-tech company (“Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, is pleased to announce the receipt of an initial contract valued at 250,000 € (approximately CA$360,000) (the “Contract”) from a European engineering services firm (the “Client”) undertaking the discovery and safe destruction of chemical warfare agents with the European Union. The contract includes a 45% upfront payment of the total contract value, or 112,500 € (approximately CA$160,000), which has already...

Continue reading

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

New In Vivo Data in Humanized Mouse Model Demonstrate that Prime Editing Can Correct Predominant Mutations Accounting for Approximately 60% of Patients with RHO adRP Up to 70% Precise Correction at RHO p.P23H Mutation and up to 65% at RHO p.V345L and p.P347L, Well Above Threshold Required to Stop Disease Progression in Photoreceptors No Detectable AAV Genome Integration and No Detectable Off-target Edits Observed Data Presented Today in an Oral Presentation at RD2023 CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of Prime Editors to efficiently and precisely correct the predominant mutations that cause rhodopsin...

Continue reading

Bridger Aerospace Terminates Proposed Public Offering of its Common Stock

BELGRADE, Mont., Oct. 24, 2023 (GLOBE NEWSWIRE) — Bridger Aerospace Group Holdings, Inc. (“Bridger” or “Bridger Aerospace”) (NASDAQ: BAER) today announced that due to market volatility and conditions, it has terminated its proposed public offering of shares of its common stock previously announced on October 17, 2023. Bridger management concluded that the current market conditions are not conducive for an offering on terms that would be in the best interests of Bridger and its stockholders. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About...

Continue reading

Manhattan Bridge Capital, Inc. Reports Third Quarter 2023 Results

GREAT NECK, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) — Manhattan Bridge Capital, Inc. (Nasdaq: LOAN) (the “Company”) announced today that its net income for the three months ended September 30, 2023 was approximately $1,446,000, or $0.13 per basic and diluted share (based on approximately 11.5 million weighted-average outstanding common shares), as compared to approximately $1,237,000, or $0.11 per basic and diluted share (based on approximately 11.5 million weighted-average outstanding common shares), for the three months ended September 30, 2022, an increase of $209,000, or 16.9%. This increase is primarily attributable to an increase in interest income from loans, partially offset by an increase in interest expense. Total revenues for the three months ended September 30, 2023 were approximately $2,434,000 compared to approximately...

Continue reading

Archrock Announces Timing for Third Quarter 2023 Results

HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) — Archrock, Inc. (NYSE:AROC) (“Archrock”) will host a conference call on Thursday, November 2, 2023, to discuss its third quarter 2023 financial and operating results. The call will begin at 12:00 p.m. Eastern Time. Archrock will release its third quarter 2023 earnings report prior to the conference call. To listen to the call via a live webcast, please visit Archrock’s website at www.archrock.com. The call will also be available by dialing 1 (833) 470-1428 in the United States, or 1 (929) 526-1599 for international calls. The access code is 492822. A replay of the webcast will be available for 90 days on Archrock’s website shortly after the call. About Archrock Archrock is an energy infrastructure company with a primary focus on midstream natural gas compression and a commitment to helping...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.